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Abstract: Extracellular acidification is a very common cause of stress in tumor microenvironment and of Darwinian 
pressure. In acid areas of the tumor, most cancer cells are-albeit slowly proliferating-more resistant to cell death 
than those in well-perfused regions. Tumor acidosis can directly regulate the expression of pro-survival proteins 
since a low extracellular pH activates the caspase-dependent cell death machinery. This mechanism has never 
been explored in bone sarcomas. We cultured osteosarcoma and Ewing sarcoma cells under low pH (pH 6.5), and 
we performed deep-sequencing and protein analysis. Both in in vitro and in vivo models, acidification activity en-
hanced tumor cells survival. However, we did not observe any change in ERK1 phosphorylation. On the contrary, 
both at the mRNA and protein level, we found a significant induction of TRAF adaptor proteins and of cIAP proteins 
(BIRC2 and/or BIRC3). As a consequence, the downstream nuclear transcription factor kappa B (NF-κB) survival 
pathway was increased. Furthermore, the treatment with the cIAP inhibitor LCL161 reverted the protection from 
apoptosis under low pH. In vitro results were confirmed both in Ewing sarcoma xenograft and in osteosarcoma 
patients, since the analysis of tumor tissues demonstrated that the levels of expression of TRAF1 or NF-κB1 signifi-
cantly correlate with the level of expression of the vacuolar ATPase (V-ATPase), the most important proton pump in 
eukaryotes. Moreover, in the tissue sections of xenograft model, the nuclear translocation of RelB, a key subunit of 
the NF-κB transcriptional complex, localized in the tumor region that also corresponded to the acid microenviron-
ment associated with the highest levels of expression of LAMP2 and V-ATPase, in the internal area of the tumor, as 
revealed by immunohistochemistry. Our data confirm that tumor acid microenvironment activates a stress-regulated 
switch to promote cell survival of bone sarcoma, and support the hypothesis that this mechanism is mediated by 
the recruitment of TRAF/cIAP complexes. Altogether, these results suggest that TRAF/cIAP can be considered as a 
target for anti-cancer therapies.
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Introduction
Interstitial acidification, i.e. decreased extracel-
lular pH (pHe), is now recognized as a hallmark 
of cancer, resulting from the combination of 
dysfunctional tissue perfusion and a high rate 
of cellular metabolism [1, 2]. Indeed, solid 
malignancies are characterized by increased 
glycolysis that sustains uncontrolled prolifera-
tion, and that results in extracellular proton 
extrusion through the activity of ion/proton 
pumps and transporters which reduce the toxic 
accumulation of protons in the cytosol. Like 
hypoxia [3], due to Darwinian pressure [4], aci-
dosis that is formed at the extracellular space, 
in turn, significantly influences cancer cell 
behavior and clinical outcome [1]. In primary 
malignant bone tumors, cancer cells have a 
high glycolytic and acidification activity that, 
with the help of several ion/proton pumps and 
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transporters [5-7], gathers an extracellular pH 
within the range 6.4-7.4 [8] which, in turn, 
strongly promotes sarcoma aggressiveness [5, 
7, 9]. Osteosarcoma is the most common malig-
nant bone tumor in children and adolescents, 
with an incidence of 4.4 per million. The peak 
age incidence is in the second decade of life, 
with a smaller peak in older adults [10, 11]. 
Ewing sarcoma is the second most common 
malignant bone tumor, with an incidence of 2.9 
per million [12]. Despite their low incidence, 
osteosarcoma and Ewing sarcoma are both 
aggressive malignant tumors that, owing to 
their rapid and invasive growth, are a dismal 
cause of mortality and disability in children. 
Clarifying the mechanisms underlying the sur-
vival of tumor cells that cause chemoresistance 
is therefore essential to improve outcomes. To 
date, several mechanisms of drug resistance 
have been indentified, including altered drug 
uptake and transport [13, 14] and apoptosis 
inhibition [15]. Our recent findings, indicate that 
in osteosarcoma a low pHe directly accounts 
for drug resistance through the inversion of pH 
gradient at the plasmalemma, resulting in a 
reduced drug uptake, or through the induction 
of lysosomal acidification and drug compart-
mentalization [7]. 
Apoptosis is a mechanisms of cell death that is 
used to maintain cellular homeostasis [16]. 
Tumor cells, and even more cancer stem cells, 
are commonly resistant to this process [17] 
as a defense mechanism. Additional indirect 
mechanisms might be involved, such as the 
activation of acid-induced anti-apoptotic intra-
cellular signaling to counteract non-permissive 
microenvironmental conditions. This might 
allow long-term survival in a hostile environ-
ment and resistance to the cytotoxicity of anti-
cancer drugs. Indeed, acidosis can directly 
regulate the expression of pro-survival and 
anti-apoptotic proteins like the BCL-2 family of 
proteins, frequently overexpressed in cancer 
and upregulated by the extracellular acid-sens-
ing receptor GPR65 [18, 19]. Extracellular aci-
dosis has also been associated with ROS pro-
duction in breast carcinoma [20], and ROS 
accumulation activates multiple pathways and 
exerts discrepant impacts on cancer cell sur-
vival in different tumor histotypes [21]. 
For the identification of effective anticancer 
strategies, an improved understanding of the 
molecular mechanisms of cancer cell survival 
is required. Most importantly, to obtain relevant 
information it is crucial to resemble, in in vitro 
preclinical models, the same stress conditions 
occurring in the tumor microenvironment. 
According to this aim and method, we intend- 
ed to dissect the anti-apoptotic mechanisms 
and the downstream molecular pathways that 
are acutely and directly promoted by extracel-




Iscove’s Modified Dulbecco’s Medium (IMDM) 
(Life Technologies, Carlsbad, California, USA); 
penicillin, streptomycin (Thermo Fisher Sci- 
entific, Waltham, Massachussetts, USA); fetal 
bovine serum (Euroclone, Milan, Italy); Matrigel 
(BD Bioscences, San Jose, California, USA); 
anti-human AKT, anti-human phospho-AKT 
(ser473), anti-human p44/42 MAP kinase, anti-
human phospho-p44/42 Map kinase/Thr202/
tyr204 (Cell Signalling Technology, Danvers, 
Massachusetts, USA); Restore Western Blot 
Stripping buffer, SuperSignal West Pico Ch- 
emiluminescent Substrate, TRIzolTM Reagent, 
BCA protein assay kit (Thermofisher Scientific, 
Waltham, Massachusetts, USA); bisBenzimide 
Hoechst 33342, rabbit anti-ATP6V1B2 anti-
body, rabbit anti-LAMP2 antibody, rabbit anti-
RelB antibody (Sigma, Saint Louis, Missouri, 
USA); TruSeq RNA Sample Prep Kit v2 (Illumina); 
NucleoSpin RNA II (Macherey-Nagel, Duren, 
Germany); Advantage RT-for-PCR Kit, Trizol 
(Life Technologies, Monza, Italy); Universal 
ProbeLibrary system (Roche Applied Science, 
Monza, Italy); TRAF1 elisa kit: Human TNF 
receptor-associated factor 1 ELISA Kit, Human 
baculoviral IAP repeat-containing protein 2/3 
(BIRC2/3) ELISA Kit (MyBiosource, San Diego, 
California, USA); Nuclear Extraction Kit (Cayman 
Chemical, Ann Arbor, Michigan, USA); ELISA-
based TransAM NFκB Family kit (Active Motif, 
Carlsbad, CA, USA); Antra 40 mg (omeprazole) 
(AstraZeneca, Cambrige, UK); LCL161 10 mM 
(Clinisciences, Nanterre, France); siRNA TRAF1 
(siRNA ID s14377) and silencer select negative 
control No. 2 (Ambion, Foster City, CA, USA),
Cell culture
HOS, Saos2, MG-63 (osteosarcoma), and A673 
(Ewing sarcoma) human cell lines were pur-
chased from the American Type Culture 
Collection, cultured in IMDM plus 20 unit/mL 
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penicillin, 100 μg/mL streptomycin, and 10% 
FBS at pH 7.4, and incubated at 37°C in a 
humidified 5% CO2 atmosphere. In assays with 
different pH, cells were seeded in medium at 
pH 7.4, and after 24 h media were changed. 
New media were set at a specific pH by us- 
ing different concentrations of sodium bicar-
bonate needed to preset pH in 5% CO2 atmo-
sphere, according to the Henderson-Hasse- 
lbach equation. During different intermediate 
time points and at the end-point of the different 
assays, the maintenance of medium pH in the 
supernatant was always as certain by a digital 
pH-meter (6230N, Jenco, San Diego, CA, USA) 
(Figure S1).
In vivo model
Procedures involving animals and their care 
were performed after institutional approval and 
in accordance with national and international 
laws and policies (EEC Council Directive 
86/609, OJ L 358, 1, Dec. 12, 1987; Italian 
Legislative Decree 116/92, Gazzetta Ufficiale 
della Repubblica Italiana n. 40, Feb. 18, 1992). 
Severe combined NOD/SCID mice were hous- 
ed and maintained in a pathogen-free en- 
vironment. A673 human cells (1 × 106) were 
subcutaneously injected with the reduced 
growth factor matrigel in the flank of 5 weeks 
old male mice (Charles River Laboratories 
International). Mice were randomly separated 
into groups and assigned to pharmacological 
treatments. Omeprazole (Antra) was reconsti-
tuted in saline solution and injected intraperito-
neally (0, 2.5, and 10 mg/kg). Treatment was 
administered 3 times per week (every other 
day) for 4 weeks, starting the day after tumor 
cells inoculation. Weights were taken during 
treatment, and drug concentrations were recal-
culated to ensure that mice received a constant 
dose of Antra. Tumor size was estimated at 
every pharmacological treatment with a caliper 
and calculated by using the formula: tumor vol-
ume [mm3] = (length [mm] × width2 [mm2])/2 
[22]. Total RNA extract were obtained using the 
acid guanidinium thiocyanate-phenol-chloro-
form method. For histological analysis, tumor 
xenografts were fixed in 10% buffered formalin 
and embedded in paraffin. Five μm sections 
were stained with hematoxylin/eosin (H&E). 
The area of necrosis was quantified by NIS ele-
ment image analysis software in 10 different 
random fields for each sample (Nikon). 
Apoptosis assay
HOS, MG63 and A673 cells (5 × 103 cells) were 
seeded on glass coverslips in complete IMDM. 
After cell adhesion, medium was changed with 
complete IMDM at pH 6.5 or 7.4. After 24 h 
apoptosis was induced by incubation of cells on 
ice for 2 h, followed by rewarming at 37°C in an 
incubator with 5% CO2 (stress thermal shock). 
After 48 hr for HOS and MG63, and after 72 h 
for A673, cells were fixed with 3.7% paraformal-
dehyde, permeabilized with PBS containing 
0.1% TritonX-100, and stained with 2.25 µg/mL 
of Hoechst 33258. Cells with apoptotic nuclear 
bodies were counted in twelve different fields 
by using 20X objective. Results were expressed 
as percentage of apoptotic cells over the field. 
Western blot
For direct immunoblotting of total protein, cells 
were serum starved for 24 h and then cultured 
for 4, 8, 12 and 24 h with medium at pH 6.5 or 
7.4. Protein lysates were obtained in RIPA buf-
fer supplemented with protease inhibitors. Cell 
lysates containing 100 µg of total proteins were 
resolved by electrophoresis on a polyacryl-
amide gel, transferred to nitrocellulose mem-
branes, and subjected to immunoblot analysis. 
Blots were probed with Phospho-44/42 MAP 
kinase or p44/42 MAP kinase or Phospho-Akt, 
or Akt polyclonal antibodies. Incubation with a 
horseradish peroxidase-conjugated anti-rabbit 
antibodies followed. To detect different anti-
gens within the same blot, nitrocellulose mem-
branes were stripped with Restore Western 
Blot Stripping buffer and reprobed. The reac-
tion was revealed by a chemiluminescence sub-
strate. Western blot were repeated thrice.
Illumina genome analyzer sequencing and 
data analysis
HOS, Saos2 and MG63 cells were cultured at 
pH 6.5 or 7.4 for 24 h. mRNA expression was 
evaluated by extracting total RNA using Trizol 
from cells cultured at pH 6.5 and pH 7.4 for 24 
h. We quantified the RNA using a Bioanalyzer 
(Agilent). The RNA integrity numbers (RIN) and 
A260/A280 ratios were all equal to 10, and 
greater than 1.8, respectively. We converted 
the total RNA to a library of template molecules 
for high-throughput DNA sequencing using the 
TruSeq RNA Sample Prep Kit v2. We quantified 
the library using a Bioanalyzer. Library (7 pM) 
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was subjected to cluster amplification to clus-
ter generation on a Single Read Flow Cell v4 
with a cluster generation instrument (Illumi- 
na). Sequencing was performed on a Genome 
Analyzer GAIIx for 76 cycles using Cycle Se- 
quencing v4 regents. Image analysis and base 
calling were performed using Off-Line Base- 
caller Software 1.6 (Illumina). Reads were 
aligned using ELAND v2 of CASAVA Software 
1.7 with the sequence data sets. Human 
genome build 19 (hg19) were downloaded from 
University of California, Santa Cruz genome 
browser (http://genome.ucsc.edu/) as the ana-
lytic reference. Transcript coverage for every 
gene locus was calculated from the total num-
ber passing filter reads that mapped, by EL- 
AND-RNA, to exons. These analyses were per-
formed using default parameters. The ad- 
vanced analysis for quantification with Quantile 
normalization algorithm was performed using 
Avadis NGS software (version1.5, Strand 
Scientific Intelligence Inc., San Francisco, CA). 
The filtering was performed using default 
parameters. We registered the obtained data 
at DDBJ/EMBL/GenBank (DRA004087 and 
DRA004091).
siRNA transfection
Specific gene silencing was obtained by siRNA 
technology associated with pipette-type elec-
troporation. A-673 cells were trypsinized at 
semi-confluence, and counted after erythro-
sine dye staining. 150 μL of cell suspension 
containing 1,500,000 cells and 2 nmol of spe-
cific siRNA TRAF1, or Silencer select negative 
control siRNA were transferred into a 1-mm 
cuvette (Neon® Transfection System, Invitro- 
gen, Life Technologies). Electroporated cells 
were transferred into 30 mL of complete medi-
um, and seeded in 12-well plates (100,000 
cells/well) for RNA isolation or in 96-well plates 
for vitality assay (7,500 cells/well). After one 
day (T0), medium was changed with complete 
medium at pH 6.5 and apoptosis was induced 
by stress thermal shock (see above). At T0, cells 
were also used to isolate RNA, as previously 
described. After additional 24 h (T1) cell num-
ber was measured by an acid phosphatase 
assay, as previously described [7]. 
Subject and sample collection
Six patients with newly diagnosed high-grade 
OS were seen at our institution from February 
2009 through July 2010, signed informed con-
sent regarding the use of their biological mate-
rials for research studies, and entered the 
study. For clinical features of the patients 
included in the study see Table 1. Tumor tis-
sues were collected after the institutional ethi-
cal committee approval (Ethics Committee of 
Istituto Ortopedico Rizzoli, No. of approval 
0033626). 
Real-time PCR
Total RNA of cells cultured at different pH was 
isolated after 24 h with the NucleoSpin RNA II. 
Total RNA extract from human or xenograft 
tumor tissues were obtained using Trizol. Total 
mRNA, obtained both from cell cultures and 
from human or xenograft tumor tissues, was 
reverse transcribed with the Advantage RT-for-
PCR Kit. The expression of baculoviral IAP 
repeat containing 2 (BIRC2) (NM_001166.4), 
baculoviral IAP repeat containing 3 (BIRC3) 
(NM_001165.4), TNF receptor-associated fac-
tor 1 (TRAF1) (NM_001190945.1), TNF rece- 
ptor-associated factor 2 (TRAF2) (NM_021- 
138.3), nuclear factor of kappa light polypep-
tide gene enhancer in B-cells 1 (NFKB1) (NM_- 
003998.3) and v-rel reticuloendotheliosis viral 
oncogene homolog B (RELB) (NM_006509.3) 
was evaluated by using the Light Cycler instru-
ment (Roche Diagnostics). One mg of cDNA was 
amplified and the Universal ProbeLibrary sys-
tem used. Probes and primers were selected by 
Table 1. Clinical and pathological features of osteosarcoma patients
Age Sex Site Histological subtype Stage
Case 1 42 F Ankle Chondroblastic Local recurrence, no lung metastases
Case 2 23 F Sacrum - Primary, no lung metastases
Case 3 62 F Distal femur Fibroblastic Recurrence with lung metastases
Case 4 67 F Proximal femur - Local recurrence, no lung metastases
Case 5 19 F Proximal tibia - Primary, no lung metastases
Case 6 51 M Proximal humerus Osteoblastic Local recurrence, no lung metastases
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using web-based assay design software Pro- 
beFinder (https://www.roche-applied-science.
com): BIRC2 fwd 5’-GACGTCATCGTGCGTCAG- 
3’, rev 5’-CGCCGACAAGGAGATACG-3’; BIRC3 
fwd 5’-CAGCAAGGCCTGTCTGTTC-3’, 5’-AATAT- 
CCCCATCCCATACAGG-3’; TRAF1 fwd 5’-TTTT- 
GGACCTGTCTCCAACAC-3’, rev 5’-CGATAAAAAT- 
CCCCTGGATG-3’; TRAF2 fwd 5’-GGAACACAC- 
CTGTCCCTCTT-3’, rev 5’-GGTCGAGCAGCATTA- 
AGGTC-3’; NFKB1 fwd 5’-CCTGGAACCACGCC- 
TCTA-3’, rev 5’-GGCTCATATGGTTTCCCATTTA-3’; 
RELB fwd 5’-GATTGTCGAGCCCGTGAC-3’, rev 
5’-CCACGCCGTAGCTGTCAT-3’; ATPase V1B2 fwd 
5’-TGGCCGAAGACTTCCTTG-3’, rev 5’-CCGAA- 
ATGCCAGTCTGAATC-3’, CA9 fwd 5’-TGCCTAT- 
GAGCAGTTGCTGT-3’, rev 5’-CCAGTCCTGGGA- 
CCTGAGT-3’; LAMP2 fwd 5’-AATGGCACAGTG- 
AGCACAAA-3’, rev 5’-GAGATGGCACAGTGGTGT- 
GT-3’. Results were expressed as ratio be- 
tween the gene of interest and the reference 
gene rRNA18s (X03205.1) (rRNA18s fwd 5’- 
GCAATTATTCCCCATGAACG-3’, rev 5’-GGGACT- 
TAATCAACGCAAGC-3’) according to the 2-ΔΔCT 
method. 
Immunostaining analyses
Tumor sections from in vivo models were depa-
raffinized and rehydrated for immunostaining. 
Five μm sections were incubated in 3% hydro-
gen peroxide solution to block the endogenous 
peroxidase reaction. Nonspecific binding was 
blocked by incubation in 5% bovine serum albu-
min. The following primary antibodies were 
used: rabbit anti-ATP6V1B2 antibody, rabbit 
anti-LAMP2 antibody, and rabbit anti-RelB anti-
body. Sections were washed, incubated with a 
biotinylated secondary antibody, covered with 
DAB and counterstained with Mayer’s hema-
toxylin. Negative controls were also performed 
by omitting the primary antibody.
ELISA assay
BIRC2/3 and TRAF1 were measured in the cells 
lysates with Human baculoviral IAP repeat-con-
taining protein 2/3, BIRC2/3 ELISA Kit and 
Human tumor necrosis factor-associated factor 
1, TRAF1 ELISA KIT according to the manufac-
turer’s instructions. The absorbance was read 
by using Infinite1 200 PRO plate reader (Tecan). 
The amount of detected BIRC2/3 and TRAF1 
was normalized based on the total protein con-
tent of the culture media, as evaluated by BCA 
method. To assess nuclear translocation of 
NF-κB component, nuclear protein extracts 
were obtained and quantified with a Nuclear 
Extraction Kit. Equal amounts of protein lysates 
were then used for NF-κB Transcription Factor 
Assay Kit quantification (TransAM) according to 
manufacturer’s instructions. The signal was 
quantified by using Infinite1 200 PRO plate 
reader (Tecan). The experiment was performed 
with four replicates.
Statistical analysis
Statistical analysis was performed with the 
StatViewTM 5.0.1 software (SAS Institute, Inc., 
Cary, Nord Carolina, USA). Due to the low num-
ber of observations, data were considered as 
not normally distributed, and nonparametric 
tests with exact p value were used. Mann-
Whitney U test was used as unpaired compari-
son of two independent variables. Wilcoxon 
signed-rank test was used for paired analysis, 
and Spearman correlation test (one-tailed) for 
the analysis of correlation. Data were exp- 
ressed as mean ± standard error (SE). Only p 
values < 0.05 were considered for statistical 
significance.
Results 
Extracellular acidosis promotes cell survival in 
bone malignant tumors 
As already demonstrated in a xenograft model 
of human osteosarcoma [7], the treatment with 
the V-ATPase inhibitor omeprazole significantly 
increased the tumor necrotic area in a xeno-
graft model of Ewing sarcoma, and already at a 
lowest dosage (Figure 1A and 1C, 2.5 mg/kg P 
= 0.0189; 10 mg/kg P = 0.003), whereas tumor 
volume was unaffected (Figure 1B). In different 
model of primary malignant bone tumors, we 
found that extracellular acidosis significantly 
reduced the percentage of apoptotic cells 
treated with a stressing thermal shock (Figure 
2A). However, the acute treatment with extra-
cellular acidosis did not promote the phosphor-
ylation of signal-regulated kinase (ERK) of MAP 
kinase (MAPK) family that is usually activated 
to induce the apoptotic process [23]. In more 
details, in HOS cells, after a few hours from 
the exposure to extracellular acid pH, we did 
observe a decrease of ERK phosphorylation 
that, however, returned to initial level already 
after 12 hours (Figure 2B), implying that the 
pro-apoptotic pathways mediated by MAPK 
were quickly counteracted by the activation of 
pro-survival signaling that prevailed already 
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after 12-24 h (Figure 2B). The lack of induction 
or inhibition of ERK phosphorylation, after 24 h 
from the acid stress was confirmed in 3 differ-
ent OS cell lines (Figure 2C).
Extracellular acidosis activates the anti-apop-
totic NF-κB pathway 
To go deeper inside the molecular pathways 
involved in acid-induced sarcoma cell survival 
that might counteract MAPK pro-apoptotic sig-
naling, we investigated whether osteosarcoma 
cells cultured at low pH showed an altered tran-
scriptome related to the anti- or pro-apoptotic 
es transduced the signals from receptors to 
nucleus when acid stress occurs. BIRC genes 
encode cellular inhibitors of apoptosis (IAPs) 
that bind the BIR domain (BIRC proteins) of TNF 
receptor family, with cIAP1 encoded by BIRC2 
and cIAP2 encoded by BIRC3. These are essen-
tial regulators of apoptosis, preventing ca- 
spase activation or interfering with pro-apop-
totic signaling intermediates [28], including 
MAP kinase pro-apoptotic signaling [29]. A 
common feature of the pro-survival NF-κB sig-
naling is to recruit during ligation different TRAF 
members at the receptor complex, at TRAF-
binding motif, together with stable cIAP pro-
Figure 1. Pharmacological inhibition of the proton pump V-ATPase causes 
tumor necrosis in a Ewing’s sarcoma xenograft model. A. A673 cells were 
subcutaneously injected in NOD/SCID mice. Mice were then treated with 
different concentration of omeprazole, a V-ATPase inhibitor (0 mg/kg n = 
14, 2.5 mg/kg n = 7, 10 mg/kg n = 14), to reduce intratumoral acidosis. 
H&E staining of tumor sections, representative images of the necrotic area, 
scale bar, 100 µm; B. Box plot of the tumor volume. Mean ± SE; C. Box plot 
of the tumor necrosis. Mean ± SE (*P < 0.05, **P < 0.01).
pathways. We found a trend of 
increase in the expression of 
anti-apoptotic genes, with par-
ticular regard to Baculoviral 
inhibitors of apoptosis repeat 
containing (BIRC) family, and a 
trend of decrease of the pro-
apoptotic family of genes 
(Figure 3A). BIRC proteins are 
deeply involved in the activa-
tion of the NF-κB signaling and, 
according to this finding, previ-
ous reports showed that acid 
extracellular stimulus exerts 
NF-κB activation [24-27]. By 
mRNA and protein analysis, we 
confirmed the same trend in 
bone sarcoma cells: with the 
exception of a slight increase 
in the Ewing sarcoma cell line 
A673 (Figure 3B), extracellular 
acidosis did not induce any 
change in NF-κB1 gene expres-
sion, but it produced, in both 
osteosarcoma and Ewing sar-
coma cells, a clear trend of 
increase of NF-κB proteins that 
are translocated into the nucle-
us, as for p50 and RelB (Figure 
3C).
Extracellular acidosis induces 
the formation of TRAF and 
cIAP complexes 
Although a great deal of evi-
dence has been amassed on 
the ligands and receptors that 
mostly activate NF-κB path- 
way, to date it is unclear which 
cytoplasmic adapter molecul- 
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teins, thereby avoiding cell death cascade [30] 
(Figure 3D). By RT-PCR analysis, we confirmed 
the trend observed by deep-sequencing data 
showing a significant increase of BIRC2 expres-
sion in MG63 osteosarcoma cells, and of TRAF1 
and TRAF2 in Ewing’s sarcoma A673 cells, and 
a trend of increased expression for BIRC3 for 
the other cell lines included in this study, with 
the exception of TRAF2 for HOS and MG63 cells 
(Figure 4A). Results on TRAF and BIRC were 
also validated by protein analysis (Figure 4B), 
suggesting the formation of a TRAF/cIAP pro-
tein complex at the BIR and TRAF domain to 
mediate anti-apoptotic signals via NF-κB activa-
tion. According to the literature, this might be 
achieved by multiple mechanisms, including 
both canonical and non-canonical NF-κB [31]. 
Also signaling via AKT is a possible mechanism 
for the activation of pro-survival NF-κB pathway 
(Figure 3D), especially after ROS production 
[20], and notably, we also found that acute aci-
dosis induced AKT phosphorylation in both the 
osteosarcoma cell lines HOS and MG63 (Figure 
4C). To strengthen the role of acidosis in pro-
moting cell survival via TRAF and BIRC proteins, 
we used different strategies. For the targeting 
of cIAP proteins and TRAF1, we used the spe-
cific inhibitor LCL161, a small molecule that 
binds with high affinity to the BIR3 domains of 
cIAP1, disengages IAPs from caspases and 
induces proteasomal degradation of cIAP-1 and 
-2, and that has been included in different clini-
cal trials [32]. For the inhibition of TRAF1, we 
used specific siRNA. Treatment of A673 cells 
with both LCL161 cIAP inhibitor and TRAF1 
siRNA caused a significant inhibition of cell via-
bility (Figure 5A-D). For LCL161 we also demon-
strated that the inhibition of cell viability was 
significantly higher at low pH in respect to pH 
7.4 (Figure 5A), and that the same drug con-
centration promoted an increase of apoptotic 
bodies in cells cultured at acid condition (Figure 
5B), For silencing experiments, although also 
the unspecific not targeted siRNA was also 
toxic for Ewing Sarcoma cells, the specific 
TRAF1 silencing was more effective in inhibiting 
the cell viability (Figure 5D). 
In conclusion, our data demonstrated that 
acute acidosis activates pro-survival signaling 
via NF-κB pathway in bone sarcoma cells th- 
rough different mechanisms.
The expression of BIRC/IAP directly correlates 
with the proton pump V-ATPase in bone sar-
coma tissues
To strengthen our hypothesis of a correlation 
between acidosis and the expression of BIRC 
and TRAF proteins, and the downstream activa-
tion of NF-κB pathway, we further analyzed in 
xenografts of Ewing Sarcoma (control group, 
the same animal models used in Figure 1A) the 
expression of BIRC2 and TRAF1 and its correla-
tion with the expression of the indirect marker 
of acidosis vacuolar proton pump V-ATPase 
V1B2 and LAMP-2, by Q-RT-PCR (Figure 5E). As 
clearly demonstrated by previous authors, 
chronic acidosis in the tumour microenviron-
ment selects for overexpression of LAMP2, 
especially at the plasma membrane [33]. To 
validate V1B2 and LAMP2 level of expression as 
both indirect markers of extracellular acidosis, 
Figure 2. The anti-apoptotic effect of extracellular 
acidosis. A. Osteosarcoma and Ewing sarcoma cells 
were cultured under different pH (6.5 and 7.4) for 24 
h and the induction of apoptosis was evaluated by 
the counting of apoptotic bodies after thermal shock. 
Mean ± SE (n = 12, **P < 0.01, ***P < 0.005); B. 
Western blot analysis of ERK phosphorylation after 
24 h of acute acidosis (pH 6.5), representative imag-
es (where not specified, cells were cultured at stan-
dard condition, at pH 7.4); C. Western blot analysis of 
ERK phosphorylation over the time, up to 24 h after 
the culturing at low pH, in HOS cells, representative 
image (where not specified, cells were cultured at 
standard condition, at pH 7.4).
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Figure 3. Extracellular acidosis promotes cell survival in bone sarcoma via the NF-κB pathway. (A) Heat map repre-
sentation of the fold increase of the expression of apoptosis and stress related-genes of osteosarcoma cells (MG63, 
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we found a significant correla-
tion between the expression of 
the two genes (Figure 5E). 
Notably, we found a significant 
correlation also between the 
expression of BIRC2 and VI1B2 
or LAMP2, and between TRAF1 
and V1B2 or LAMP2 (Figure 
5E). We further confirmed by 
immunohistochemistry of con-
secutive tissue sections of the 
same in vivo models that RelB 
activation (nuclear transloca-
tion) localized at the same 
region of the tumor where ex- 
tracellular acidosis localized, 
as revealed by the staining of 
both V1B2 in the intracellular 
vesicles of tumors cells (cyto-
plasmic punctate patterns), 
and by the staining of LAMP2 
(both in the intracellular vesi-
cles and at the cell membrane 
of tumor cells) (Figure 6). 
Finally, to confirm in clinical 
setting the data obtained in 
preclinical models, we ana-
lyzed a small number of sam-
ples of tumor tissues obtained 
from patients with osteosarco-
ma and we looked for the cor-
relation between the mRNA 
expression of different pro-
teins of the NF-κB pathway. As 
a confirmation of the forma- 
tion of the TRAF-cIAP complex, 
although we did not find a cor-
relation between BIRC3 ex- 
pression and TRAF (data not 
shown), we found a significant 
correlation between TRAF1 
and TRAF2 expression, and a 
trend of correlation between 
HOS, Saos-2) after short-term acidosis. mRNA were analyzed by deep-sequencing after that cells were cultured at 
pH 6.5 compared to physiological medium (pH 7.4) for 24 h. Colors on the heat map indicate the log2 ratios of ex-
pression (representing normalized read counts). Red, upregulation; green, downregulation. (B) Cells were cultured 
under different pH (6.5 and 7.4) for 24 h as described in (A), and NF-κB mRNA expression and activation were quan-
tified in cell lysates. (C) NF-κB1 (p50) and RelB nuclear protein concentration of osteosarcoma and Ewing sarcoma 
cells. Mean ± SE (n = 3 for HOS and MG63, and n = 5 for A673, *P < 0.05). (D) Signaling pathways of the tumor 
necrosis factor receptor (TNFR) family that mediates both survival and apoptotic pathways. The draw represents the 
pathways and adaptor molecules that are involved in the signaling that follows the acid stress: the NF-κB activation 
pathway via Akt (1), via the canonical pathway (2), via the non-canonical pathway (3), the activation of the AP1 com-
plex transcriptional factor (4), and the TRAF-mediated death signaling with the activation of caspase cascade (5).
Figure 4. Extracellular acidosis promotes the induction of BIRC and TRAF 
expression. A. RT-qPCR analysis of the TRAF1 and 2 and of the BIRC2 and 
3 expression in cells treated at the same condition of Figure 3A. Mean ± SE 
(n = 5, *P < 0.05); B. Protein quantification of TRAF and BIRC family of pro-
teins in cells treated at the same condition of Figure 3A (statistical paired 
analysis, *P < 0.05), for 6 and 24 h. Mean ± SE (n = 3, P was obtained by 
Wilcoxon Rank paired analysis considering each osteosarcoma cell line as 
a single value); C. Western blot of AKT and the phosphorylated form in cells 
treated with acid medium (pH 6.5) for 24 h.
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TRAF1 and BIRC2 (Figure 7A). Notably, as we 
already found in Ewing’s sarcoma xenografts, 
TRAF1 expression also significantly correlated 
with the expression of the V1B2 subunit of the 
proton pump V-ATPase, meaning that TRAF1 is 
the major TRAF protein recruited at the TRAF 
motif after the induction of the acid stressing 
stimulus (Figure 7B). The level of expression of 
TRAF1 also significantly correlated with those 
of both NF-κB1 (p50) and RelB, whereas TRAF2 
level correlated only with RelB (Figure 7C). In 
turn, as the final effector of the acid-stress-
mediated pro-survival signaling, p50 signifi-
cantly correlated with the V-ATPase V1B2 (Figure 
7D). Interestingly, we also found a trend of cor-
relation between carbonic anhydrase 9 (CA9) 
and RelB (Figure 7D). CA9 is enzymes that cat-
alyze the interconversion between carbon diox-
ide and water and the dissociated ions of car-
bonic acid with the net results of increasing 
proton concentration, and is responsible for 
intratumoral acidosis in several types of can-
cer, including sarcomas [34-36]. However, CA9 
expression did not correlate with none of the 
other players of the non-canonical NF-κB path-
way in human osteosarcoma tissue samples, 
implying that CA9 might activate NF-κB signal-
ing via different pathways.
Discussion
Due to the high expression of the most impor-
tant proton pump V-ATPase [37, 38], tumor 
cells from osteosarcoma and other types of 
sarcoma strongly acidify the extracellular space 
[5, 7, 35]. Proton pump inhibitors like omepra-
zole can block the V-ATPase activity [39] in dif-
ferent sarcoma cell types [35], and the com-
bined treatment of doxorubicin and omeprazole 
in osteosarcoma xenografts significantly re- 
duced tumor volume and increased the tumor 
necrosis [7]. Also in a pilot study with osteo- 
sarcoma patients, the use of omeprazole in 
combination with doxorubicin and other con-
ventional chemotherapeutics increased the 
necrotic index [6]. We hypothesized that, follow-
ing omeprazole treatment and following the 
blocking of proton pumping, alkalinisation of 
the extracellular space paralleled the cytosolic 
acidification, ultimately leading to a reversal of 
the pH gradient at the plasma membrane of 
tumor cells. This is a permissive condition for 
the intracellular uptake and enhanced cytotox-
icity of doxorubicin [7]. Indeed, under physio-
logical conditions, pH homeostasis inside/out-
side the cell is crucially balanced and has to 
be strictly maintained to keep a selective per-
meability to different agents at the plasmalem-
ma. Furthermore, in the early nineties, several 
authors have reported that pH homeostasis 
most importantly accounts for the life/death 
balance of the single cell as intracellular acidifi-
cation is concomitant of cell death [40-43]. 
Falling in line with this concept, here we specu-
lated that, in a symmetrical way, acidification of 
the extracellular environment, followed by intra-
cellular alkalinisation in cancer cells [44], is 
a pro-survival signal, and that the increased 
cytotoxicity of doxorubicin in osteosarcoma, 
when combined with omeprazole, was due both 
to a high drug uptake and to the blockage 
of pH-mediated pro-survival signaling that fol-
lows omeprazole-induced intracellular acidifi-
cation. As a matter of fact, in a xenograft model, 
omeprazole produced a trend of increase of 
the necrotic tumor area also as a single treat-
ment [7]. Likewise, in this study, in a Ewing 
sarcoma xenograft, omeprazole significantly 
enhanced tumor necrosis in a dose-dependent 
manner, and acute exposure to a low pHe pro-
moted in vitro a reduction of the number of 
apoptotic cells after a thermal shock in both 
Ewing and osteosarcoma cells. We thus went 
deeper inside into the apoptosis-related mo- 
lecular machinery that is regulated by pH 
homeostasis. 
Multiple stress-inducible molecules, including 
c-Jun N-terminal kinase (JNK), mitogen-activat-
ed protein kinase (MAPK)/extracellular signal-
regulated protein kinase (ERK), NF-κB or 
ceramide have been involved in transmitting 
the apoptotic signal [45]. Among these, the 
MAPK are key regulators and inducers of cell 
Figure 5. Targeting of cIAP protein or of TRAF1 inhibit cell viability of A673 cells when cultured in acid condition. 
A. Inhibition of cell viability as verified by cell counting after the treatment with LCL161 (25 mM). The inhibitor was 
more effective at pH 6.5 than at pH 7.4. Mean ± SE (n = 3, *P < 0.05); B. Induction of apoptosis as verified by the 
counting of apoptotic bodies after the treatment with LCL161 (25 mM) of cells cultured at low pH (6.5). Mean ± SE 
(n = 3, *P < 0.05); C. mRNA analysis of TRAF1 expression by Q-RT-PCR after the treatment with specific siRNA at 
low pH (pH 6.5); D. Inhibition of cell viability as verified by acid phosphatase indirect assay after the treatment with 
specific siRNA at low pH (pH 6.5). Mean ± SE (n = 19, ****P < 0.001); E. Correlation of mRNA level between differ-
ent proteins of the TRAF-cIAP destruction complex in Ewing sarcoma xenografts with acid-related markers V-ATPase 
V1B2 or LAMP2 (n = 6, *P < 0.05, **P < 0.01).
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apoptosis [46]. In our model, acid stress pro-
duced an inhibition of ERK1 (p44 MAPK) phos-
[30]. Regarding the non canonical pathway, 
NF-κB-inducing kinase (NIK) activates the 
Figure 6. Immunoistaining of Ewing sarcoma xenografts showing the same 
localization for the indirect markers of acidosis V1B2, LAMP2, and the nu-
clear localization of RelB, a subunit of the NF-κb transcription complex that 
can be activated by the TRAF-cIAP destruction complex. (A) H&E staining 
of a section a representative xenograft of Ewing’s sarcoma model of the 
control group shown in Figure 1 (scale bar, 200 µm, 4 × objective). We fo-
cused our investigation on an external and an internal region of the tumor. 
(B) Consecutive tissue sections of the section showed in (A), and stained 
for different antigens. For LAMP2 and V1B2 in the left panel, lower magni-
fication (scale bar 200 µm, 4 × objective), and in the right panels, higher 
magnification of the specified area unlighted at low magnification by the 
rectangle (scale bar 20 µm, objective 60 ×). Note in the rectangle showing 
an enlarged detail, for V-ATPase, the staining is punctuated suggesting a 
intracellular vesicular localization, for LAMP2 is both punctuated and at the 
cytoplasmic membrane. For RelB, only high magnification of the two differ-
ent regions, external and internal are shown (scale bar 20 µm, objective 
60 ×). Note in the rectangle showing an enlarged detail that cytoplasm was 
always positive, whereas nuclei in the internal region were almost stained 
suggesting the nuclear translocation of the protein, whereas in the external 
region of the tumor only a small fraction of nuclei were stained.
phorylation. However, this inhi-
bition was fully replaced at 12 
hours, suggesting that pro-sur-
vival pathways might prevail. 
As a confirmation, by wide-
screening analysis, after acute 
incubation with acidosis, the 
molecular signature confirmed 
a clear trend of induction of 
pro-survival mechanisms rath-
er than the activation of pro-
apoptotic signaling in bone sar-
coma cells. 
In diverse cell types, Rel/NF-κB 
transcription factors have a 
role in regulating the apoptotic 
program, either as essential 
for the induction of apoptosis 
or, perhaps more commonly, 
as blockers of apoptosis [47]. 
In particular, NF-κB pathway 
plays a central role in the cel-
lular response to stress and is 
also known as a redox-sensi-
tive transcription factor acti-
vated by reactive oxygen spe-
cies (ROS). Notably, acidosis 
induces the generation of ROS 
which can be suppressed by 
ROS scavengers [20], and our 
previous works have demon-
strated in MSC, sharing with 
sarcoma cells a mesenchymal 
origin, a strong induction of 
the expression of members of 
the NF-κB pathway, like RelB 
and p50 or p52, after the 
acid stress stimulus [24, 25]. 
Likewise, in this study we 
observed NF-κB activation in 
acid-induced bone sarcoma 
cells, with an increase in 
NF-κB1 (p50) and RelB protein 
expression. 
The NF-κB transcription factor 
family consists of 5 subunits-
p65 (RelA), p105/p50, c-Rel, 
RelB, and p100/p52-acting as 
dimers in two distinct path-
ways-the classical (or canoni-
cal) pathway and alternative 
(or non-canonical) pathway 
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downstream kinase IκB kinase-α (IKKα) that 
triggers p100 phosphorylation and processing 
to produce p52 and a RelB-specific inhibitor 
[30] (point 3 in Figure 3D). The activity of NIK is 
strongly determined by its degradation that, in 
turn, is modulated by the TRAF-IAP complex 
[31]: the continuous degradation of NIK induced 
by TRAF3 prevents NIK accumulation and 
NF-κB pathway activation; adversely, when liga-
tion of specific TNFR superfamily members by 
their ligands occurs, TRAF2, TRAF3, cIAP1 and 
cIAP2 are recruited to the receptor complex 
and TRAF3 ubiquitilated and degraded, thereby 
resulting in stabilization and accumulation of 
NIK and the induction of p100 processing, fol-
lowed by the translocation of NF-κB p52-RelB 
heterodimers into the nucleus [48]. Among the 
most expressed genes stimulated by acute aci-
dosis, we found an up-regulation of the TRAF1 
and TRAF2 and of cIAP1 (BIRC2) and cIAP2 
(BIRC3). These observations suggest that, 
under acidosis, TRAF/cIAP protein complexes 
form at the receptor complex and, simultane-
ously NIK leads to the formation of active RelB 
and p52 NF-κB pro-survival transcriptional 
complex. Furthermore, previous data showing 
that TRAF-mediated NF-kappaB activation sup-
presses the TNF-induced ROS accumulation 
that subsequently induces prolonged MAPK 
activation and necrotic cell death [49] appar-
ently justify the temporary ERK1 inhibition that 
we observed in sarcoma cells cultured in acid 
medium. 
In summary, by this study we demonstrated 
that in osteosarcoma and Ewing sarcoma cell 
lines the acid-promoted expression of TRAF 
proteins parallels with the increased expres-
sion of cIAP proteins, suggesting that TRAF 
activity is mainly devoted to the activation of 
the pro-survival signaling mediated by NF-κB 
pathway. We also confirmed our hypothesis by 
using cIAP specific inhibitor and TRAF1 silenc-
ing approaches. With the exception of TRAF6 
expression in osteosarcoma that correlated 
with a high Enneking score [50], and of BIRC5, 
that has been considered as a poor prognostic 
marker in Ewing sarcoma [51], the role of TRAF 
proteins and cIAP have never been evaluated in 
sarcoma. As reflected by their name, cIAP were 
initially characterized as endogenous inhibitors 
of caspases. In particular, XIAP block caspase 
activation by binding to caspases -3, -7, and -9 
via the BIR domains and negatively regulate 
both the intrinsic and extrinsic apoptosis path-
ways [52]. In addition to the non-canonical 
pathway via ubiquitination events of TRAF3 pro-
tein (point 3 in Figure 3D), cIAP cause the non-
degradative ubiquitination of RIP1 and the fol-
lowing activation of inhibitor of NF-κB kinase 
(IKK, IkB kinase b) in the canonical NF-κB path-
way (point 2 in Figure 3D). This leads to the 
phosphorylation and proteasomal degradation 
of IkBa followed by nuclear translocation of 
NF-κB subunits (p50). In addition to regulate 
cell survival and inflammation, both cIAP and 
TRAF proteins, with a lesser extent for cIAP, can 
also mediate the activation of MAPKK, result-
ing in the induction of the transcription of cyto-
kines and regulators of cell differentiation [52, 
53] (point 4 in Figure 3D), whereas TRAF alone 
can activate the FADD/caspase death signaling 
(point 5 in Figure 3D). Finally, according to our 
data, in addition to the signaling pathway medi-
ated by the formation of the complex between 
the adaptor protein TRAF and the IAP proteins, 
acidosis might also activate a pro-survival sig-
naling after TNFR activation via the NF-κB 
inflammatory pathway through the phosphory-
lation of Akt (point 1, Figure 3D) [54, 55]. This 
is not the first time that the Akt signaling is 
observed after acid stress, as it was already 
detected in breast cancer [20]. The involve-
ment of the NF-κB complex downstream the 
acid-induced cIAP/TRAF activities was also 
demonstrated by both mRNA analysis and 
immunohistochemistry of Ewing’s sarcoma 
xenograft since the level of expression of the 
indirect marker of acidosis, the most important 
acidifying protein in eukariotic cells V-ATPase, 
and LAMP2, lysosome-associated membrane 
protein, significantly correlated with both BIRC2 
and TRAF1. Moreover, nuclear staining of RelB 
Figure 7. The expression of BIRC/IAP mRNA directly correlate with the expression of the acidifying proton pump 
V-ATPase in tumor tissues from osteosarcoma patients. A. Correlation of mRNA level between different proteins 
of the TRAF-cIAP destruction complex in human osteosarcoma tissue samples; B. Correlation of the V-ATPase V1b2 
with TRAF1 expression; C. Correlation of the mRNA expression of the different proteins of the TRAF-cIAP destruction 
complex with the mRNA expression of the proteins of the NF-κB complex; D. Correlation of proton pump and trans-
porters with the mRNA expression of the proteins of the NF-κB complex. For all the analysis, Mean ± SE (n = 5, *P 
< 0.05, Spearman correlation test). 
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in the tumor cells was found in the same inter-
nal region of the tumor that was also positive 
for V-ATPase in the lysosomal compartment, 
and for LAMP2, both at the plasma membrane 
level and in the lysosomes. Indeed, as reported 
by Damaghi et al., LAMP2 is located at the plas-
ma membrane in clinical samples of breast 
cancer and this redistribution is acid-induced in 
in vitro model of the same type of cancer [33]. 
The internal regions of the tumor are most likely 
also the more hypoxic region and, thus, the 
most acid.
Finally, similarly to what we observed in animal 
models, by the analysis of tumor samples from 
osteosarcoma patients, as a clear demonstra-
tion of our hypothesis, we showed a strong 
correlation between the TRAF and cIAP mRNA 
contents, and downstream between the con-
centration of NF-κB1, with the acidification 
activity, which was indirectly quantified by the 
analysis of the level of the expression V-ATPase. 
Indeed, even by analyzing a small number of 
samples, we found not only a significant corre-
lation between BIRC2 and TRAF1 or between 
TRAF1 and NF-κB, as expected, but also a sig-
nificant correlation between V1B2 and TRAF1 or 
between V1B2 and NF-κB1 (p50). During evolu-
tion, the eukaryotic V-ATPases have acquired a 
unique regulatory mechanism of regulation of 
proton-pumping activity. Moreover, the eukary-
otic V-ATPases have also acquired alternative 
roles, including as a receptor to sense and 
transmit transmembrane signaling as well as to 
directly and indirectly modulate the trafficking 
and signaling of other cellular receptors [56]. In 
particular, we have previously demonstrated 
that the level of expression of the V1B2 isoform 
of the B subunit of the V1 domain in several 
Ewing sarcoma cells directly correlates with the 
extent of the acidification activity and of tumor 
aggressiveness [5]. 
High levels of IAPs are detected in many tumors, 
and this is often associated with chemoresis-
tance, metastasis, and poor prognosis [57]. 
IAPs are thus attractive pharmacologic targets 
for ameliorating therapeutic resistance in can-
cers. Several small molecule IAP inhibitors and 
antagonists, also known as second mitochon-
dria-derived activator of caspases (SMAC) 
mimetic after the endogenous inhibitor, have 
been developed, some of which have been test-
ed in phase I and II clinical trials [58]. According 
to our data, the use of these inhibitors might 
thus be considered for the identification of 
novel and more effective therapies in bone 
sarcomas.
In conclusion, by using both in vitro and in vivo 
preclinical models, and by the analysis of tumor 
tissues derived from bone sarcoma patients, 
we indirectly demonstrated that intratumoral 
acidosis is a crucial feature of bone sarcoma 
since it is an important trigger of pro-survival 
signaling via cIAP/TRAF/NF-κB pathway. These 
key adaptor and effector proteins might be 
thus considered as important markers of resis-
tance to the therapy and considered as effec-
tive therapeutic targets. 
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Figure S1. pH value of the culture supernatant over time. The supernatant of the respective cell culture was centri-
fuged and immediately used for pH measurement. N = 3 (mean ± SE).
